The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Programmed cell death 1 (PD-1) and its ligand (PD-L1) expression in thymic epithelial tumors (TETs): Impact on the treatment efficacy and alteration in expression after chemotherapy (C).
 
Yuki Katsuya
No Relationships to Disclose
 
Hidehito Horinouchi
Honoraria - Johnson & Johnson; Lilly; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical (Inst)
 
Tetsuhiko Asao
No Relationships to Disclose
 
Shinsuke Kitahara
No Relationships to Disclose
 
Kuniko Sunami
No Relationships to Disclose
 
Yoshitaka Seki
No Relationships to Disclose
 
Yasushi Goto
Consulting or Advisory Role - Boehringer Ingelheim; Lilly
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Shintaro Kanda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst)
 
Yutaka Fujiwara
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst)
 
Hiroshi Nokihara
Honoraria - Boehringer Ingelheim; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Noboru Yamamoto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Novartis (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Koji Tsuta
No Relationships to Disclose
 
Shun-ichi Watanabe
No Relationships to Disclose
 
Yuichiro Ohe
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche Pharma AG; Sanofi; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Novartis; Ono Pharmaceutical; Roche Pharma AG
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)